For­mer Al­ler­gan pro­gram posts pos­i­tive topline PhI­II re­sults in pres­by­opia in an R&D win post-Ab­b­Vie merg­er

The bat­tered pipeline Ab­b­Vie $AB­BV ac­quired in its $63 bil­lion buy­out of Al­ler­gan picked up a rare win Wednes­day morn­ing.

Al­ler­gan an­nounced that a pair of Phase III stud­ies for an ex­per­i­men­tal oph­thalmic so­lu­tion in pres­by­opia, an age-re­lat­ed con­di­tion re­sult­ing in a prob­lem fo­cus­ing on near­by ob­jects, met their pri­ma­ry end­point in vi­sion tests as­so­ci­at­ed with the con­di­tion. The da­ta puts the pro­gram on track for a NDA some­time in the first half of next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER